CoChat
Sign Up
Cited by 196HIV/AIDS Research and InterventionsReproductive Health and ContraceptionCervical Cancer and HPV Research

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women.

Open access
Polis, Chelsea B., Curtis, Kathryn M., Hannaford, Philip C., Phillips, Sharon J., Chipato, Tsungai, Kiarie, James N., Westreich, Daniel J., Steyn, Petrus S.·2016·AIDS
DOI 10.1097/qad.0000000000001228PMC PMC5106090
Open this paper in CoChat — free account

Abstract

OBJECTIVE AND DESIGN: Some studies suggest that specific hormonal contraceptive methods [particularly depot medroxyprogesterone acetate (DMPA)] may increase women's HIV acquisition risk. We updated a systematic review to incorporate recent epidemiological data. METHODS: We searched for articles published between 15 January 2014 and 15 January 2016 and hand-searched reference lists. We identified longitudinal studies comparing users of a specific hormonal contraceptive method against either nonusers of hormonal contraception or users of another specific hormonal contraceptive method. We added newly identified studies to those in the previous review, assessed study quality, created forest plots to display results, and conducted a meta-analysis for data on DMPA versus non-use of hormonal contraception. RESULTS: We identified 10 new reports of which five were considered 'unlikely to inform the primary question'. We focus on the other five reports, along with nine from the previous review, which were considered 'informative but with important limitations'. The preponderance of data for oral contraceptive pills, injectable norethisterone enanthate, and levonorgestrel implants do not suggest an association with HIV acquisition, though data for implants are limited. The new, higher quality studies on DMPA (or nondisaggregated injectables), which had mixed results in terms of statistical significance, had hazard ratios between 1.2 and 1.7, consistent with our meta-analytic estimate for all higher quality studies of hazard ratio 1.4. CONCLUSION: Although confounding in these observational data cannot be excluded, new information increases concerns about DMPA and HIV acquisition risk in women. If the association is causal, the magnitude of effect is likely hazard ratio 1.5 or less. Data for other hormonal contraceptive methods, including norethisterone enanthate, are largely reassuring.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/qad.0000000000001228

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Identification of newly included studies.
Fig. 1 Identification of newly included studies.CC BY · PubMed Central
Fig. 2 Use of oral contraceptives (versus non-use of hormonal contraception) and HIV acquisition, among 11 studies considered informative but with important limitations.
Fig. 2 Use of oral contraceptives (versus non-use of hormonal contraception) and HIV acquisition, among 11 studies considered informative but with important limitations.CC BY · PubMed Central
Fig. 3 Use of injectables (depot medroxyprogesterone acetate, norethisterone enanthate, or unspecified injectable) versus non-use of hormonal contraception and HIV acquisition, among 12 studies considered informative but with important limitations.
Fig. 3 Use of injectables (depot medroxyprogesterone acetate, norethisterone enanthate, or unspecified injectable) versus non-use of hormonal contraception and HIV acquisition, among 12 studies considered informative but with important limitations.CC BY · PubMed Central
Fig. 4 Use of depot medroxyprogesterone acetate (or unspecified injectable) versus non-use of hormonal contraception and HIV acquisition, among 12 studies considered informative but with important limitations.
Fig. 4 Use of depot medroxyprogesterone acetate (or unspecified injectable) versus non-use of hormonal contraception and HIV acquisition, among 12 studies considered informative but with important limitations.CC BY · PubMed Central
Fig. 5 Use of norethisterone enanthate versus non-use of hormonal contraception and HIV acquisition, among six studies considered informative but with important limitations.
Fig. 5 Use of norethisterone enanthate versus non-use of hormonal contraception and HIV acquisition, among six studies considered informative but with important limitations.CC BY · PubMed Central
Fig. 6 Hormonal contraceptive methods and HIV acquisition in head-to-head studies, among two studies considered informative but with important limitations.
Fig. 6 Hormonal contraceptive methods and HIV acquisition in head-to-head studies, among two studies considered informative but with important limitations.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

Sorted by citations

Items 101–196 of 196

Related

See all

Metadata

Authors
Polis, C. B., Curtis, K. M., Hannaford, P. C., Phillips, S. J., Chipato, T., Kiarie, J. N., Westreich, D. J., & Steyn, P. S.
Affiliations
Boston University (US)
Corresponding author
Polis, Chelsea B.
ORCID
Venue
AIDS
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-11-13
Volume
30
Issue
17
Pages
2665-2683
ISSN
0269-9370 (ISSN-L)
DOI
10.1097/qad.0000000000001228
PMC
PMC5106090
OpenAlex
W2544080039
Cited by
196
References
75
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 16 · 2020: 31 · 2019: 39 · 2018: 37 · 2017: 21 · 2016: 8
FWCI
5.38
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • AIDS (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
Funders
  • World Health Organization
  • National Institutes of Health (NIH DP2, DP2‐HD‐08‐4070, 1dp2hd084070-01)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R24HD074034, DP2-HD-08-4070)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords
hormonal contraception, HIV acquisition, women, depot medroxyprogesterone acetate, injectable contraceptives, oral contraceptives, norethisterone enanthate, levonorgestrel implants, HIV risk, confounding
MeSH terms
Contraception, Contraceptive Agents, Female, Female, Humans, HIV Infections, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review